Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient

Han, Seung-Hee; Park, Hye Sun; Lee, Yong-Ho; Lee, Byung Wan; Kang, Eun Seok; Soo, Bong

doi:10.12771/emj.2016.39.1.14

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SSRIs may cause hypoglycemia via different mechanisms, such as an increase in insulin sensitivity, interaction with sulfonylureas in their metabolism, and a decrease in gluconeogenesis ( Derijks et al, 2008 ; Ghaeli et al, 2004 ; Han et al, 2016 ; Santra, Banerjee, Munshi, & Chaudhuri, 2015 ). Hydroxychloroquine can induce symptomatic or asymptomatic hypoglycemia in diabetic and nondiabetic patients ( Unübol, Ayhan, & Guney, 2011 ).…”

Section: Methodsmentioning

confidence: 99%

Drug Interactions of Psychiatric and COVID-19 Medications

Mohebbi

Talebi

Moghadamnia

et al. 2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a pandemic with 1771514 cases identified in the world and 70029 cases in Iran until April 12, 2020. The co-prescription of psychotropics with COVID-19 medication is not uncommon. Healthcare providers should be familiar with many Potential Drug-Drug Interactions (DDIs) between COVID-19 therapeutic agents and psychotropic drugs based on cytochrome P450 metabolism. This review comprehensively summarizes the current literature on DDIs between antiretroviral drugs and chloroquine/hydroxychloroquine, and psychotropics, including antidepressants, antipsychotics, mood stabilizers, and anxiolytics. Methods: Medical databases, including Google Scholar, PubMed, Web of Science, and Scopus were searched to identify studies in English with keywords related to psychiatric disorders, medications used in the treatment of psychiatric disorders and COVID-19 medications. Results: There is a great potential for DDIs between psychiatric and COVID-19 medications ranging from interactions that are not clinically apparent (minor) to those that produce lifethreatening adverse drug reactions, or loss of treatment efficacy. The majority of interactions are pharmacokinetic interactions via the cytochrome P450 enzyme system. Conclusion: DDIs are a major concern in the comorbidity of psychiatric disorders and COVID-19 infection resulting in the alteration of expected therapeutic outcomes. The risk of toxicity or lack of efficacy may occur due to a higher or lower plasma concentration of medications. However, psychiatric medication can be safely used in combination with COVID-19 pharmacotherapy with either a wise selection of medication with the least possibility of interaction or careful patient monitoring and management.

show abstract

Section: Methodsmentioning

confidence: 99%

Drug Interactions of Psychiatric and COVID-19 Medications

Mohebbi

Talebi

Moghadamnia

et al. 2020

Basic Clin. Neurosci. J.

View full text Add to dashboard Cite

show abstract

Paroxetine

2016

Reactions Weekly

View full text Add to dashboard Cite

Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review

Wichart,

Yoeun,

Chin

et al. 2024

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

BackgroundPharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data.ObjectiveOur objective was to synthesize published data for the treatment of depression, bipolar and related disorders, schizophrenia or psychotic disorders, and anxiety disorders in adults receiving hemodialysis or peritoneal dialysis.MethodsWe undertook a scoping review, searching the following databases: Medline, Embase, CINAHL, PsycINFO, Cochrane Library, Scopus, and Web of Science. Data on patients who received only short‐term dialysis, a kidney transplant, or non‐pharmacologic treatments were excluded.ResultsSeventy‐three articles were included: 41 focused on depression, 16 on bipolar disorder, 13 on schizophrenia and psychotic disorders, 1 on anxiety disorders, and 2 addressing multiple mental health illnesses. The majority of depression studies reported on selective serotonin reuptake inhibitors (SSRIs) as a treatment. Sertraline had the most supporting data with use of doses from 25 to 200 mg daily. Among the remaining SSRIs, escitalopram, citalopram, and fluoxetine were studied in controlled trials, whereas paroxetine and fluvoxamine were described in smaller reports and observational trials. There are limited published data on other classes of antidepressants and on pharmacological management of anxiety. Data on treatment for patients with bipolar disorder or schizophrenia and related disorders are limited to case reports.ConclusionOver half of the studies included were case reports, thus limiting conclusions. More robust data are required to establish effect sizes of pharmacological treatments prior to providing specific recommendations for their use in treating mental health illnesses in patients receiving dialysis.

show abstract

Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient

Cited by 3 publications

References 10 publications

Drug Interactions of Psychiatric and COVID-19 Medications

Drug Interactions of Psychiatric and COVID-19 Medications

Paroxetine

Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review

Contact Info

Product

Resources

About